摘要
目的对鳖甲煎丸治疗慢性乙型肝炎肝纤维化的有效性及安全性进行评价。方法计算机检索Pub Med、The Cochrane Library、CNKI、WANFANG、VIP,纳入符合标准的临床随机对照试验(RCT)进行方法学质量评价,并采用Rev Man5.3软件进行Meta分析。结果 Meta分析结果显示:鳖甲煎丸在改善透明质酸[MD=71.13,95%CI(25.06,117.20),P=0.002]、层黏蛋白[MD=33.02,95%CI(17.32,48.72),P<0.000 1]、Ⅲ型胶原[MD=66.36,95%CI(32.36,100.36),P=0.000 1]方面均有统计学差异,在改善Ⅳ型胶原[MD=12.18,95%CI(-18.07,42.44),P=0.43]方面无统计学差异。结论现有证据显示,鳖甲煎丸治疗CHB肝纤维化具有一定的疗效。但结论还需更多高质量文献进一步证实。
Objective To systematically review the efficacy and safety of Bie jia jian Wan in the treatment of chronic hepatitis B fibrosis. Methods We search Pub Med, The Cochrane Library, CNKI, VIP and WANFANG. Methodological quality assessment is incorporated into clinical randomized controlled trials（RCT）,then meta-analysisis performed using RevMan5.3 software. Results The results of meta-analysis show that Bie jia jian Wan in improving the level of HA[MD = 71.13, 95 % CI（25.06, 117.20）, P = 0.002]、LN[MD = 33.02, 95 % CI（17.32,48.72）, P 0.000 1]、PCIII [MD = 66.36, 95 % CI（32.36, 100.36）, P = 0.000 1] are statistically differences, no significant difference in the improvement of the level of IVC[MD = 12.18, 95 % CI（-18.07, 42.44）, P = 0.43]. Conclusion The current evidence shows that Bie jia jian Wan treatment has certain curative effect in patients with chronic hepatitis B fibrosis. But this conclusion requires more high-quality literature to further verify.
出处
《现代中药研究与实践》
CAS
2018年第1期71-75,共5页
Research and Practice on Chinese Medicines
基金
北京市朝阳区协同创新资助项目(No.XC1420)
